si:dkeyp-13a3.3 Antibody

What is the si:dkeyp-13a3.3 protein and why is it significant in zebrafish research?

The si:dkeyp-13a3.3 gene encodes an uncharacterized protein in zebrafish (Danio rerio) that belongs to the same gene family as si:dkeyp-13a3.10, which encodes a 227 amino acid transmembrane protein . These proteins are significant in zebrafish research as potential developmental regulators and molecular markers. Analysis of related proteins in this family shows they typically contain transmembrane domains with distinctive N- and C-terminal regions that can be targeted by specific antibodies . Their expression patterns during zebrafish development make them valuable for studying tissue specification, organogenesis, and molecular signaling pathways in vertebrate development.

What are the key considerations when selecting antibodies against zebrafish si:dkeyp-13a3.3?

When selecting antibodies against zebrafish si:dkeyp-13a3.3, researchers should prioritize several factors:

• Epitope location: Determine whether N-terminal, C-terminal, or internal (M-terminal) epitopes are most relevant to your experimental question .

• Antibody format: Consider whether monoclonal combinations or individual monoclonals are more appropriate for your study.

• Cross-reactivity profile: Evaluate potential cross-reactivity with similar proteins in the si:dkeyp family or other zebrafish proteins .

• Validation methods: Prioritize antibodies validated through multiple methods (ELISA, Western blot, immunohistochemistry) and in zebrafish tissues specifically .

• Secondary modifications: Consider how post-translational modifications might affect antibody binding, as secondary modifications within binding epitopes may lead to reduced signal (false negatives) .

Analysis of related antibodies shows that monoclonal combinations targeting distinct epitopes often provide more comprehensive detection across experimental conditions .

How do researchers confirm the specificity of si:dkeyp-13a3.3 antibodies?

Confirming antibody specificity for si:dkeyp-13a3.3 requires a multi-step validation approach:

• Peptide array analysis: Test binding against synthetic peptides representing the target protein and related sequences. This method can reveal potential cross-reactivity and the influence of post-translational modifications on antibody binding .

• Western blot validation: Verify single-band detection at the expected molecular weight (approximately 25-30 kDa based on related proteins) in zebrafish tissue lysates .

• Knockout/knockdown controls: Compare antibody binding in wild-type tissues versus si:dkeyp-13a3.3 knockdown/knockout samples to confirm specificity.

• Immunoprecipitation followed by mass spectrometry: Identify all proteins captured by the antibody to assess potential off-target binding.

• Cross-reactivity testing: Evaluate binding to closely related proteins like si:dkeyp-13a3.10 (which shares sequence similarity) .

Research shows that even highly-specific antibodies may exhibit unexpected cross-reactivity or be influenced by neighboring modifications, necessitating thorough validation specific to each experimental system .

What are the optimal conditions for using si:dkeyp-13a3.3 antibodies in immunohistochemistry of zebrafish tissues?

Optimal conditions for immunohistochemistry with si:dkeyp-13a3.3 antibodies require careful optimization:

Fixation protocol:

• 4% paraformaldehyde for 24 hours at 4°C for adult tissues

• 2-4% paraformaldehyde for 2-4 hours for embryos/larvae

Antigen retrieval:

• Heat-mediated retrieval using 10mM sodium citrate buffer (pH 6.0) for 15 minutes

• Alternative: Proteinase K treatment (10 μg/ml for 10 minutes) for membrane epitopes

Blocking and permeabilization:

• 5-10% normal serum with 0.3% Triton X-100 in PBS for 1-2 hours

• Add 1% BSA to reduce background

Primary antibody incubation:

• Optimal dilution typically ranges from 1:200 to 1:1000 based on ELISA titer data (10,000 titer corresponds to approximately 1 ng detection sensitivity on Western blot)

• Incubate 12-24 hours at 4°C for best signal-to-noise ratio

Signal detection:

• Fluorescent secondary antibodies at 1:500-1:1000 provide optimal visualization

• Alternative: HRP-conjugated systems with careful optimization of development time

Comparative studies with related antibodies demonstrate that overnight incubation at 4°C typically results in superior signal-to-noise ratio compared to shorter incubations at room temperature .

How can researchers optimize Western blot protocols for si:dkeyp-13a3.3 detection?

Optimizing Western blot protocols for si:dkeyp-13a3.3 detection requires several technical considerations:

Sample preparation:

• Use RIPA buffer with protease inhibitor cocktail for membrane protein extraction

• Heat samples at 70°C (not 95°C) for 10 minutes to prevent aggregation of transmembrane domains

Gel and transfer conditions:

• 12-15% polyacrylamide gels provide optimal resolution

• Transfer to PVDF membranes (rather than nitrocellulose) for transmembrane proteins

• Use wet transfer at 30V overnight at 4°C for efficient transfer of hydrophobic proteins

Blocking and antibody incubation:

• 5% non-fat dry milk in TBST is recommended for blocking

• Primary antibody dilution at 1:1000 (based on 10,000 ELISA titer)

• Incubate primary antibody overnight at 4°C

Detection optimization:

• Enhanced chemiluminescence systems with film exposure times of 30 seconds to 5 minutes

• Alternative: fluorescent secondary antibodies for quantitative analysis

Studies with similar antibodies targeting transmembrane proteins in zebrafish show that PVDF membranes generally provide better signal retention than nitrocellulose, and extended transfer times improve detection of hydrophobic domains .

What approaches can be used to quantify si:dkeyp-13a3.3 expression levels in developmental studies?

Quantifying si:dkeyp-13a3.3 expression during development requires integrated approaches:

Western blot quantification:

• Densitometric analysis normalized to loading controls (β-actin or GAPDH)

• Standard curves using recombinant protein for absolute quantification

qRT-PCR correlation:

• Parallel analysis of protein (antibody-based) and mRNA levels

• Calculation of protein:mRNA ratios to identify post-transcriptional regulation

Whole-mount immunohistochemistry quantification:

• Fluorescence intensity measurements across developmental timepoints

• Z-stack confocal imaging with 3D reconstruction for spatial quantification

Flow cytometry:

• Single-cell suspensions from dissociated tissues

• Permeabilization protocols optimized for transmembrane proteins

For developmental studies, a combined approach using both qRT-PCR and antibody-based protein detection provides the most comprehensive analysis, as post-transcriptional regulation often results in discrepancies between mRNA and protein levels during key developmental transitions .

How do researchers address potential cross-reactivity between si:dkeyp-13a3.3 antibodies and related protein targets?

Addressing potential cross-reactivity requires systematic evaluation and control strategies:

Peptide array screening:

• Test antibody binding against synthetic peptides from si:dkeyp-13a3.3 and related proteins

• Identify specific cross-reactive epitopes through overlapping peptide analysis

Absorption controls:

• Pre-incubate antibody with excess target peptide to verify binding specificity

• Compare results with and without absorption to identify non-specific signals

Multiple antibody validation:

• Use antibodies targeting different epitopes (N-terminal, C-terminal, and M-terminal)

• Compare binding patterns across different antibodies to distinguish specific from non-specific signals

Knockout/knockdown controls:

• Compare antibody binding patterns in wildtype versus gene-edited samples

• Confirm signal reduction/elimination in knockout samples

Research demonstrates that even highly-specific antibodies can show unexpected cross-reactivity, with some H3K27me3 antibodies cross-reacting with H4K20me3 or other modified histones despite being raised against specific epitopes . This highlights the critical importance of comprehensive validation for zebrafish antibodies.

What impact do post-translational modifications have on si:dkeyp-13a3.3 antibody binding?

Post-translational modifications can substantially impact antibody binding through several mechanisms:

Epitope masking effects:

• Phosphorylation, glycosylation, or other modifications near the epitope can sterically hinder antibody access

• Studies with histone antibodies demonstrate that phosphorylation at adjacent residues can completely abolish binding to methylated lysines

Conformational changes:

• Modifications may alter protein folding, affecting accessibility of discontinuous epitopes

• Transmembrane proteins are particularly susceptible to conformation-dependent epitope accessibility

Quantification challenges:

• Modified forms may represent varying percentages of total protein

• Modification-sensitive antibodies can produce false negatives when the primary epitope is present but modified

Research with histone antibodies demonstrates that seemingly minor modifications can dramatically impact binding specificity, with H3K9me3 antibody #11 showing weaker binding to H3K9me3/S10ph than to H3K9me3 alone, while antibody #10 bound both peptides equally .

How can epitope mapping improve interpretation of si:dkeyp-13a3.3 antibody data?

Epitope mapping provides critical insights for data interpretation:

Benefits of detailed epitope knowledge:

• Predicts potential cross-reactivity based on sequence homology

• Anticipates effects of post-translational modifications

• Explains discrepancies between different antibodies targeting the same protein

Mapping methodologies:

• Peptide array analysis: Tests binding to overlapping synthetic peptides representing the entire protein sequence

• Alanine scanning mutagenesis: Identifies critical binding residues

• Hydrogen/deuterium exchange mass spectrometry: Maps conformational epitopes

• X-ray crystallography or cryo-EM: Provides atomic-level detail of antibody-antigen interfaces

Application to data interpretation:

• Understanding whether antibodies recognize linear vs. conformational epitopes affects protocol optimization

• Knowing specific binding motifs helps predict potential cross-reactivity with related proteins

• Identifying modification-sensitive residues within epitopes explains variable detection across samples

Studies with histone antibodies demonstrate that epitope mapping can reveal "false negatives" when modifications near the primary epitope inhibit antibody binding, and "false positives" when antibodies cross-react with similar epitopes in unrelated proteins .

What are the most common sources of false negative results with si:dkeyp-13a3.3 antibodies and how can researchers address them?

False negative results with si:dkeyp-13a3.3 antibodies can arise from multiple sources:

Epitope masking by post-translational modifications:

• Adjacent modifications can prevent antibody binding despite protein presence

• Solution: Use antibodies targeting different epitopes or modification-insensitive regions

Insufficient protein extraction:

• Transmembrane proteins require specialized extraction protocols

• Solution: Optimize lysis buffers with appropriate detergents (RIPA, NP-40, or SDS)

Fixation-induced epitope masking:

• Over-fixation can cross-link proteins and mask epitopes

• Solution: Titrate fixation times and perform antigen retrieval optimization

Sample processing artifacts:

• Proteolytic degradation during sample preparation

• Solution: Use fresh samples with protease inhibitors and appropriate storage

Developmental or tissue-specific isoforms:

• Alternative splicing may eliminate epitopes in certain contexts

• Solution: Use antibodies targeting conserved regions or multiple antibodies

Research with histone antibodies demonstrates that secondary modifications near primary epitopes can completely prevent antibody binding, creating false negatives. For example, antibody #19 directed against H3K27me3 did not bind to peptides carrying additional modifications like R26me2a or S28ph .

How should researchers validate antibody lots to ensure consistent results across experiments?

Rigorous lot validation ensures experimental reproducibility:

Initial validation protocol:

• ELISA titer determination: Compare binding curves between lots

• Western blot analysis: Verify band pattern and intensity consistency

• Immunostaining comparison: Assess signal localization and intensity

• Positive and negative control samples: Include samples with known expression

Quantitative metrics for lot comparison:

• Signal-to-noise ratios across detection methods

• Binding affinity measurements via surface plasmon resonance

• Detection limits in serial dilutions of target protein

Record-keeping and standardization:

• Document lot numbers in all publications and protocols

• Maintain reference samples for inter-lot comparisons

• Create standard operating procedures for validation

For critical experiments, researchers should consider purchasing sufficient quantities of a single lot to complete entire studies, as even minor manufacturing variations can affect antibody performance . When lot changes are unavoidable, side-by-side validation with previous lots is essential to calibrate data interpretation.

What controls are essential when interpreting immunohistochemistry results with si:dkeyp-13a3.3 antibodies?

Essential controls for immunohistochemistry include:

Negative controls:

• No primary antibody: Reveals background from secondary antibody

• Isotype control: Unrelated antibody of same isotype/host species

• Pre-absorption control: Primary antibody pre-incubated with excess antigen

• Genetic knockdown/knockout: Tissues lacking target protein

Positive controls:

• Known expressing tissues: Samples with established expression patterns

• Overexpression systems: Cells/tissues with forced expression

• Multiple antibody validation: Comparison with antibodies targeting different epitopes

Technical controls:

• Autofluorescence control: Sample processed without any antibodies

• Counterstaining: Nuclear (DAPI) and cytoskeletal markers for localization context

• Z-stack analysis: Full-thickness imaging to verify complete tissue penetration

Research with histone antibodies demonstrates that apparently specific antibodies can show significant cross-reactivity to unrelated epitopes. For instance, antibody #20 directed against H3K27me3 showed strong cross-reactivity with H4K20me3 . These findings emphasize the critical importance of comprehensive controls for accurate data interpretation.

How can researchers employ si:dkeyp-13a3.3 antibodies in live imaging applications?

Utilizing si:dkeyp-13a3.3 antibodies for live imaging requires specialized approaches:

Antibody fragments for live imaging:

• Fab or single-chain fragments improve tissue penetration

• Site-specific conjugation to fluorophores preserves binding capacity

• Optimized buffer compositions for maintaining antibody stability in vivo

Microinjection approaches:

• Direct injection of fluorescently-labeled antibodies into zebrafish embryos

• Concentration optimization to balance signal intensity and toxicity

• Time window determination for optimal imaging (typically 30 minutes to 4 hours post-injection)

Advanced imaging techniques:

• Light sheet microscopy for reduced phototoxicity during extended imaging

• Confocal resonance scanning for improved depth penetration

• Dual-color imaging with membrane markers for co-localization studies

When employing antibodies for live imaging, researchers must balance concentration (signal intensity) against potential interference with normal protein function. Evidence from studies with other transmembrane protein antibodies suggests that Fab fragments at concentrations of 0.1-0.5 mg/ml provide optimal signal-to-interference ratios .

What approaches can integrate si:dkeyp-13a3.3 antibody data with transcriptomic and proteomic datasets?

Integrating antibody data with -omics approaches provides systems-level insights:

Multi-modal data integration strategies:

• Correlative analysis: Compare protein detection patterns with mRNA expression data

• Temporal profiling: Align developmental expression patterns across modalities

• Spatial integration: Overlay antibody staining patterns with spatial transcriptomics

Validation frameworks:

• Use antibody detection to verify translation of transcripts identified in RNA-seq

• Confirm protein interactions identified in proteomics through co-immunoprecipitation

• Validate subcellular localization predictions through immunohistochemistry

Computational integration approaches:

• Machine learning algorithms to identify correlation patterns

• Network analysis to place si:dkeyp-13a3.3 in functional pathways

• Bayesian integration of multiple data types for confidence scoring

Integrated analysis often reveals that protein abundance does not directly correlate with mRNA levels due to post-transcriptional regulation, highlighting the importance of combining antibody-based detection with transcriptomic data .

How can epitope-specific antibodies distinguish between si:dkeyp-13a3.3 protein variants and modified forms?

Epitope-specific antibodies enable sophisticated protein variant discrimination:

Strategies for variant-specific detection:

• Isoform-specific epitopes: Target unique sequences in alternatively spliced regions

• Junction-spanning antibodies: Design epitopes that bridge exon-exon junctions

• Modification-specific antibodies: Target known post-translational modification sites

Technical approaches:

• Peptide array screening to identify variant-specific binding profiles

• Competitive ELISA to quantify relative abundance of variants

• Sequential immunoprecipitation to isolate specific subpopulations

Application to functional studies:

• Subcellular fractionation combined with variant-specific detection

• Developmental timing analysis of variant expression

• Pathway activation correlation with specific modifications

Research with histone antibodies demonstrates that highly specific antibodies can distinguish between nearly identical epitopes differing only in modification state. For example, different H3K27me3 antibodies showed distinct binding profiles when additional modifications like S28ph were present . Similar approaches can be applied to distinguish between si:dkeyp-13a3.3 variants.

What experimental design factors should researchers consider when planning studies with si:dkeyp-13a3.3 antibodies?

Comprehensive experimental design requires consideration of multiple factors:

Biological variables:

• Developmental stage-specific expression patterns

• Sex-specific differences in expression

• Strain background effects on protein levels

• Environmental variables affecting expression

Technical variables:

• Tissue preservation method compatibility with epitope

• Sample processing effects on protein detection

• Antibody concentration optimization for each application

• Detection system sensitivity and dynamic range

Experimental controls:

• Genetic knockdown/knockout validation

• Multiple antibody confirmation

• RNA-protein correlation analysis

• Reference standard inclusion for quantitative studies

Statistical considerations:

• Power analysis for sample size determination

• Appropriate statistical tests for data type

• Blinding procedures for subjective assessments

• Replication strategy (biological vs. technical)

Research with histone antibodies demonstrates that experimental design must account for epitope accessibility in different contexts, as fixation, embedding, and retrieval methods can dramatically affect antibody binding to the same target .

How can multiplexed immunodetection approaches enhance si:dkeyp-13a3.3 research?

Multiplexed detection provides contextual insights into protein function:

Technical approaches for multiplexing:

• Sequential staining: Multiple rounds of staining/stripping

• Spectral unmixing: Simultaneous detection of spectrally similar fluorophores

• Mass cytometry: Metal-tagged antibodies for high-parameter detection

• DNA-barcoded antibodies: Sequential detection through DNA hybridization

Optimal protein combinations:

• Co-staining with known interaction partners

• Developmental markers for stage-specific contextualization

• Subcellular compartment markers for localization precision

• Signaling pathway components for functional correlation

Data analysis approaches:

• Colocalization quantification methods

• Neighborhood analysis in tissue contexts

• Machine learning for pattern recognition

• Trajectory analysis across developmental timepoints

Studies with antibodies against other transmembrane proteins demonstrate that multiplexed approaches can reveal contextual regulation that would be missed by single-parameter analysis. For example, patterns of post-translational modification on neighboring proteins can provide insights into functional state that are not apparent from target protein detection alone .

What emerging technologies are likely to enhance si:dkeyp-13a3.3 antibody applications in zebrafish research?

Several emerging technologies hold promise for advancing si:dkeyp-13a3.3 research:

Next-generation antibody formats:

• Nanobodies (single-domain antibodies) for improved tissue penetration

• Bispecific antibodies for simultaneous targeting of multiple epitopes

• Intrabodies optimized for intracellular expression and live imaging

Advanced imaging technologies:

• Super-resolution microscopy for nanoscale localization

• Expansion microscopy for improved spatial resolution

• Light-sheet microscopy for whole-organism imaging with reduced phototoxicity

Functional antibody applications:

• Antibody-mediated protein degradation for targeted knockdown

• Proximity-labeling antibodies for identification of interaction partners

• Optogenetic antibody systems for spatiotemporal control of protein function

AI-enhanced analysis:

• Automated image segmentation and quantification

• Deep learning for pattern recognition across developmental stages

• Predictive modeling of protein expression and localization

The integration of these technologies with traditional antibody applications will enable researchers to address increasingly sophisticated questions about si:dkeyp-13a3.3 function in zebrafish development and physiology .

How might comparative studies across species inform the functional understanding of si:dkeyp-13a3.3?

Cross-species comparison provides evolutionary and functional insights:

Evolutionary conservation analysis:

• Identification of conserved domains across vertebrates

• Mapping of conserved post-translational modification sites

• Comparison of expression patterns in homologous tissues

Functional complementation approaches:

• Cross-species rescue experiments to test functional conservation

• Chimeric protein studies to identify species-specific domains

• Heterologous expression systems for comparative biochemistry

Translational relevance:

• Identification of human homologs for disease modeling

• Conservation analysis of regulatory pathways

• Therapeutic target potential assessment

Comparative antibody studies require careful epitope selection to ensure recognition of conserved regions across species. Studies with histone antibodies demonstrate that even highly conserved proteins can show species-specific modifications that affect antibody binding , necessitating specialized validation for cross-species applications.